Resistance is inevitable in ROS1-rearranged NSCLC, leading HCC78 cells to acquire KRAS G12C, amplify KRAS and FGF3, and sustain ERK activation [171]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.